MRK1

113.45

+1.29%↑

SHL.DE

46.61

-0.83%↓

ARGX

480.4

+0.02%↑

FRE

42.49

+0.9%↑

ONC.US

254.32

-4.58%↓

MRK1

113.45

+1.29%↑

SHL.DE

46.61

-0.83%↓

ARGX

480.4

+0.02%↑

FRE

42.49

+0.9%↑

ONC.US

254.32

-4.58%↓

MRK1

113.45

+1.29%↑

SHL.DE

46.61

-0.83%↓

ARGX

480.4

+0.02%↑

FRE

42.49

+0.9%↑

ONC.US

254.32

-4.58%↓

MRK1

113.45

+1.29%↑

SHL.DE

46.61

-0.83%↓

ARGX

480.4

+0.02%↑

FRE

42.49

+0.9%↑

ONC.US

254.32

-4.58%↓

MRK1

113.45

+1.29%↑

SHL.DE

46.61

-0.83%↓

ARGX

480.4

+0.02%↑

FRE

42.49

+0.9%↑

ONC.US

254.32

-4.58%↓

Search

Sanofi SA

Open

SectorHealthcare

82.81 0.55

Overview

Share price change

24h

Current

Min

82.32

Max

83.43

Key metrics

By Trading Economics

Income

1.4B

1.9B

Sales

3B

11B

P/E

Sector Avg

16.677

50.291

EPS

1.79

Dividend yield

4.71

Profit margin

17.65

Employees

82,878

EBITDA

2.2B

2.8B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.91% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.71%

2.40%

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

-29B

101B

Previous open

82.26

Previous close

82.81

News Sentiment

By Acuity

34%

66%

97 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Sanofi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 cze 2025, 07:27 UTC

Acquisitions, Mergers, Takeovers

Barclays, Santander Interested in Sabadell's U.K. Unit TSB, Bloomberg Says, Citing Sources

11 cze 2025, 08:25 UTC

Acquisitions, Mergers, Takeovers

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

2 cze 2025, 16:05 UTC

Major Market Movers

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2 cze 2025, 09:17 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 cze 2025, 05:31 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22 maj 2025, 12:02 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22 maj 2025, 00:06 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Vigil Neuroscience for About $470 Million

20 cze 2025, 08:36 UTC

Market Talk

Predictability of U.K. Banks Has Value -- Market Talk

20 cze 2025, 07:10 UTC

Market Talk

Strong Correction Unlikely for Spanish Banks -- Market Talk

10 cze 2025, 12:18 UTC

Earnings

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

2 cze 2025, 13:50 UTC

Earnings
Acquisitions, Mergers, Takeovers

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 cze 2025, 12:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2 cze 2025, 10:50 UTC

Acquisitions, Mergers, Takeovers

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 cze 2025, 10:05 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 cze 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 cze 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 cze 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 cze 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 cze 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 cze 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 cze 2025, 05:03 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Blueprint Medicines Corporation

2 cze 2025, 05:02 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Acquire Blueprint Medicines Corporation

30 maj 2025, 08:58 UTC

Hot Stocks

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 maj 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27 maj 2025, 05:03 UTC

Acquisitions, Mergers, Takeovers

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27 maj 2025, 05:00 UTC

Acquisitions, Mergers, Takeovers

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21 maj 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 maj 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 maj 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 maj 2025, 23:23 UTC

Acquisitions, Mergers, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

38.91% upside

12 Months Forecast

Average 114.266 EUR  38.91%

High 127 EUR

Low 95 EUR

Based on 17 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

12

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

91.3 / 96.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

97 / 380 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.